We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Trial Reporting Gains Momentum, Amid Stakeholders Concerns
Mandatory reporting of clinical trial results under the FDA Amendments Act (FDAAA) is picking up steam, but generic- and brand-drug stakeholders have voiced potential concerns about the system.